Chlorambucil Cytotoxicity Reduction in Rats Through Bone Marrow, An In vivo Study

Author(s): Ebtesam H.O. Nafie*, Eman Khater, Mohamed Awwad, Mohamed Zowail, Kholud Hegazy

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 18 , Issue 15 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Bone Marrow (BM) has the self-renovation capacity and has been used recently in tumor medicine. Chlorambucil [CHB] is ordinarily utilized chemotherapy to treat varieties of malignancy patients. This investigation intended to gauge the effectiveness of BM as an in-vivo antimutagenic against CHB.

Methods: The experimental design relies upon four classes; each class contains ten adult male albino rats as follows: control, rats infused orally with CHB for fourteen days, rats intravenously infused with BM through a tail vein one time, rats infused the mix of CHB and BM.The Anticancer capability of BM was assessed by cytogenetic assay and mitotic index. The declarations of the apoptosis- related genes were examined by RT-qPCR examination.

Results: The present experiment demonstrated a curative effect of BM against the cytotoxic impact of CHB. Infusion of BM after chemotherapy helps to diminish the chromosomal aberration; increment mitotic index and decline the Bax/Bcl2 proportion compared with [CHB] class gather that prompts expanding the survival rate of influenced cells with chemotherapy cytotoxicity.

Conclusion: The present study shows that bone marrow transplantation together after CHB infusion helps to increase genomic stability by diminishing structural chromosome abnormalities, diminishing the Bax/Bcl2 proportion and increasing the mitotic index.

Keywords: Chlorambucil, bone marrow, chromosomal aberration, BAX, BCL-2, RT-qPCR.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [2187 - 2192]
Pages: 6
DOI: 10.2174/1871520618666180907170317
Price: $65

Article Metrics

PDF: 26
PRC: 1